期刊文献+

临床药师参与尿毒症合并肺部感染患者药物治疗的实践与分析

Practice and Analysis of Drug Treatment by Clinical Pharmacists in Patients with Uremia and Pulmonary Infection
下载PDF
导出
摘要 目的:通过临床药师参与尿毒症合并肺部感染患者的药物治疗,以有效控制患者尿毒症合并肺炎感染。方法:根据慢性肾功能不全治疗的规范和患者的病情变化,临床药师为患者制定针对性的治疗方案,对患者产生的并发症及药物不良反应相应地修正方案,全程监护患者用药。结果:临床药师通过对尿毒症合并肺部感染患者进行药学监护,医师予以采纳药师意见,有效控制了患者的感染,治愈后出院。治疗实践中对此类患者的用药有了更加深入的认识,在抗菌药物的应用上确保安全性及合理性。结论:临床药师在临床实践中对尿毒症合并肺部感染的患者实施抗感染治疗,有利于临床合理用药以及药物治疗水平的提高。 Objective: Drug treatment in patients with uremia and pulmonary infection through clinical pharmacists in order to effectively control the infection of patients with uremia pneumonia. Methods: According to the standard of treatment of chronic renal failure and the change of patient's condition, clinical pharmacists formulate targeted treatment plan for patients, modify the program of complications and adverse drug reactions, and monitor patients' medication in the whole process. Results::Clinical pharmacists carry out pharmaceutical care for patients with uremia combined with pulmonary infection, and doctors adopt pharmacists' opinions, effectively control the infection of patients, and discharge after being cured. In clinical practice, clinical pharmacists have a deeper understanding of the use of drugs for patients with uremia and pulmonary sensation, and ensure safety and rationality in the application of antibiotics. Conclusion:: Clinical pharmacists in the clinical practice of uremic pulmonary infection patients with anti infection treatment, is conducive to the rational use of drugs and improve the level of drug therapy.
作者 赵希青 Zhao Xiqing(NO.6 People’s Hospital of Zhengzhou, Zhengzhou, Henan, 450015)
出处 《现代医用影像学》 2019年第4期919-920,923,共3页 Modern Medical Imageology
关键词 尿毒症 肺部感染 临床药师 药学监护 Uremia Pulmonary infection Clinical pharmacist Pharmaceutical care
  • 相关文献

参考文献5

二级参考文献42

  • 1周华,凌丽燕,杨青,俞云松,陈亚岗,李兰娟,郑树森.人苍白杆菌耐药性及AmpC酶研究[J].中华检验医学杂志,2005,28(4):378-380. 被引量:22
  • 2黄华,彭常军,李彬,徐传彬,高国全,陆淼泉.人苍白杆菌分离株部分生物学性状的研究[J].中华检验医学杂志,2005,28(10):1022-1024. 被引量:6
  • 3陶方明.从痰中分离出多重耐药的人苍白杆菌1株[J].检验医学与临床,2007,4(4):341-342. 被引量:1
  • 4杨莉梅,刘彩霞,李素.尿毒症患者真菌感染的临床调查与分析[J].中华医院感染学杂志,2007,17(4):410-411. 被引量:3
  • 5Deliere E,VuThien H, Levy V, et al. Epidemiological investiga-tion of 0chrobactrum anthropi strains isolated from a haematology unit [J]. J Hosp Infect, 2000, 44(3) :173 -178.
  • 6Cieslak TJ, Drabick C J, Robb ML. Pyogenic Infectious due to Ochrobactrum anthropi [ J ]. Clin Infect Dis, 1996, 22 ( 5 ) : 845 -847.
  • 7Higgins CS, Avison MB, Jamieson L, et al. Characterization, cloning and sequence analysis of the inducible Ochrobactrum an- thropi AmpC beta-lactamase [ J ]. J Antimicrob Chemother, 2001, 47(6) :745-754.
  • 8Nadjar D, Labia R, Cerceau C, et al. Molecular characterization of chromosomal class C beta-lactamase and its regulatory gene in Ochrobactrum anthropi [ J ]. Antimicrob Agents Chemother, 2001,45 (80) :2324-2330.
  • 9Plesinac-Karapandzic V,Masulovic D,Markovic B,et al.Per-cutaneous nephrostomy in the management of advanced andterminal-stage gynecologic malignancies:outcome and compli-cations. European Journal of Gynaecological Oncology . 2010
  • 10Dolgikh TI,Kaftyreva LA,Votovich MA,et al.Verotoxin asa major laboratory criterion for Escherichia coliO157-inducedenteric infection complicated by hemolytic uremic syndrome ininfants in the Omsk region. Klinicheskaia Laboratornaia Diagnostika . 2010

共引文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部